WO2001074817A1 - Derives d'hydrazide - Google Patents

Derives d'hydrazide Download PDF

Info

Publication number
WO2001074817A1
WO2001074817A1 PCT/JP2001/002674 JP0102674W WO0174817A1 WO 2001074817 A1 WO2001074817 A1 WO 2001074817A1 JP 0102674 W JP0102674 W JP 0102674W WO 0174817 A1 WO0174817 A1 WO 0174817A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrocarbyl
different
same
hydrazide derivatives
ring
Prior art date
Application number
PCT/JP2001/002674
Other languages
English (en)
Japanese (ja)
Inventor
Akira Suga
Masanori Miura
Naoki Imanishi
Hideki Kubota
Hiroshi Moritani
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Priority to AU2001244635A priority Critical patent/AU2001244635A1/en
Publication of WO2001074817A1 publication Critical patent/WO2001074817A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés d'hydrazide représentés par la formule générale suivante (I). L'excellente activité d'inhibition sur la sécrétion des lipoprotéines associées à l'apolipoprotéine B, confère aux dérivés d'hydrazide une utilité en tant que médicaments contre l'hyperlipidémie et, de préférence, en tant qu'agents entraînant la baisse du cholestérol et des triglycérides. Dans cette formule, le cycle A représente un cycle pyridine ou benzène éventuellement substitué, Z1 représente un alkylène inférieur, R1 et R3 peuvent être identiques ou différents et représentent chacun un atome d'hydrogène, un groupe hydrocarbyle, un groupe hétérocycle, etc., R4 et R5 peuvent être identiques ou différents et représentent chacun un atome d'hydrogène, un groupe halogéno, un groupe hydrocarbyle, etc., et R7 et R9 peuvent être identiques ou différents et représentent chacun un atome d'hydrogène, un groupe hydrocarbyle, etc.
PCT/JP2001/002674 2000-03-30 2001-03-29 Derives d'hydrazide WO2001074817A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001244635A AU2001244635A1 (en) 2000-03-30 2001-03-29 Hydrazide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-093056 2000-03-30
JP2000093056 2000-03-30

Publications (1)

Publication Number Publication Date
WO2001074817A1 true WO2001074817A1 (fr) 2001-10-11

Family

ID=18608293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002674 WO2001074817A1 (fr) 2000-03-30 2001-03-29 Derives d'hydrazide

Country Status (2)

Country Link
AU (1) AU2001244635A1 (fr)
WO (1) WO2001074817A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051382A1 (fr) * 2003-11-28 2005-06-09 Astellas Pharma Inc. Agent renforçant l'effet hypolipidemiant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0799828A2 (fr) * 1996-04-04 1997-10-08 Bayer Ag Pyrimido [1,2-a] indoles
US5684014A (en) * 1994-10-04 1997-11-04 Bayer Aktiengesellschaft Cycloalkano-indole and -azaindole derivatives
US5952498A (en) * 1996-04-04 1999-09-14 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido 1,2a! indolcarboxcyclic acids and their activated derivatives
EP0950661A1 (fr) * 1998-04-17 1999-10-20 Eli Lilly And Company Composés tricycliques substitués pour le traitement des maladies induites par sPLA2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684014A (en) * 1994-10-04 1997-11-04 Bayer Aktiengesellschaft Cycloalkano-indole and -azaindole derivatives
EP0799828A2 (fr) * 1996-04-04 1997-10-08 Bayer Ag Pyrimido [1,2-a] indoles
US5952498A (en) * 1996-04-04 1999-09-14 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido 1,2a! indolcarboxcyclic acids and their activated derivatives
EP0950661A1 (fr) * 1998-04-17 1999-10-20 Eli Lilly And Company Composés tricycliques substitués pour le traitement des maladies induites par sPLA2

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051382A1 (fr) * 2003-11-28 2005-06-09 Astellas Pharma Inc. Agent renforçant l'effet hypolipidemiant

Also Published As

Publication number Publication date
AU2001244635A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
EP1219609A4 (fr) Composes cycliques aromatiques azotes a six elements
EP1669352A4 (fr) Derive thiazoline et utilisation
WO2005095409A3 (fr) Derives de tetrahydroquinoline et procede d’elaboration desdits derives
CA2286723A1 (fr) Composes tricycliques
EP1642880A4 (fr) Inhibiteur de proteines de la famille hsp90
MXPA04006322A (es) Derivados de 6-fluorobiciclo[3.1.0]hexano.
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
WO2000071510A3 (fr) INHIBITEURS DU FACTEUR Xa
MXPA04001253A (es) Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
ES2048109A1 (es) Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
NZ514662A (en) Amine derivatives
EP1156045A4 (fr) Derives d'amides et compositions de medicaments
EP1026149A4 (fr) Derives d'acide amidocarboxylique
EP1813270A4 (fr) Inhibiteurs des proteines de la famille hsp90
WO2004014860A3 (fr) Composes heterocycliques fusionnes
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
CA2226894A1 (fr) Derives de 2-(4-substitue)-benzylamino-2-methylpropanamide
WO1999000373A8 (fr) Derives de benzimidazole
EP0943613A4 (fr) Composes heterocycliques d'oxygene
EP1184373A4 (fr) Composes tricycliques
EP1500652A4 (fr) Derive et medicament de quinazoline
WO2003004497A1 (fr) Compose heterocyclique
CA2226886A1 (fr) Derives d'aminolactames n-(4-substitue-benzyl)-2
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
WO1999004770A3 (fr) Composition pharmaceutique active dans la reduction de production de proteine mcp-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572507

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase